SXC Health solutions announces second quarter financial results

Aug 04, 2011, 06:00 ET from SXC Health Solutions Corp.

SXC posts record results and revises guidance upward

LISLE, IL, Aug. 4, 2011 /PRNewswire/ - SXC Health Solutions Corp. ("SXC" or the "Company") (NASDAQ: SXCI, TSX: SXC), a leading provider of technology and pharmacy benefit management ("PBM") services, announces its financial results for the three-month and six-month periods ended June 30, 2011.

Q2 2011 Highlights

  • Revenue grew 153% on a year over year basis to $1.2 billion, compared to $479.4 million in Q2 2010
  • Gross profit was $74.2 million, compared to $53.7 million in Q2 2010
  • Adjusted EBITDA¹ increased 32% to $41.4 million, compared to $31.5 million in Q2 2010
  • GAAP net income increased to $21.6 million, or $0.34 per share (fully-diluted), compared to $17.1 million, or $0.27 per share (fully-diluted), in Q2 2010
  • Non-GAAP adjusted earnings per share¹ (fully-diluted), which excludes amortization of intangible assets, increased 31% to $0.38, compared to $0.29 in Q2 2010
  • Adjusted prescription claim volume¹ for the PBM segment was 22.8 million, compared to 11.8 million in Q2 2010
  • Transaction processing volume for the Health Care Information Technology ("HCIT") segment was 98.1 million, compared to 99.6 million in Q2 2010
  • Generic dispense rate increased to 78% compared to 74% in Q2 2010
  • Successfully converted an HCIT client to PBM services in the quarter
  • Announced a three-year HCIT service contract with HealthPlus of Michigan serving 215,000 members
  • Announced expanded relationship with HealthSpring Inc., to add approximately $1 billion in annual drug spend from its Bravo Health acquisition effective January 1, 2012
  • Announced a five-year sub-contract from HP Enterprise Services to provide PBM services to the State of Nevada's 180,000 Medicaid members
  • Announced a three-year HCIT service contract with Health Alliance Plan of Michigan, serving 500,000 members
  • Completed the acquisition of MedMetrics Health Partners, Inc. ("MedMetrics"), a full-service PBM and previously a client of SXC
  • Subsequent to quarter end announced the acquisition of PTRX, Inc. and SaveDirectRx, Inc., both previously a client of SXC

"We continued to show strong revenue, adjusted EBITDA and gross profit growth during Q2 with the ramp up of the Optima account and the HealthSpring contract in full swing," said Mark Thierer, Chairman, CEO and President of SXC.  "As we increase our scale and enhance our services through organic and acquisitive growth, our opportunity to compete for new business is only getting better. We are right in the middle of the selling season and we have already exceeded our plan for new wins this year. We are also continually identifying opportunities to expand our flexible and customized programs with existing clients through our mail and specialty pull-through strategies and our industry leading generic utilization."

Financial Review Revenue and gross profit segmented by PBM and HCIT: SXC evaluates segment performance based on revenue and gross profit. Reconciliations of the Company's business segments to the consolidated financial statements for the three and six months ended June 30, 2011 and 2010 are as follows:

Three Months Ended June 30,                        
(in thousands)                          
    PBM     HCIT     Consolidated
      2011   2010     2011   2010     2011   2010
Revenue     $ 1,182,856   $ 451,295   $ 29,183   $ 28,151   $ 1,212,039   $ 479,446
Cost of  revenue     1,122,501     412,681     15,335     13,026     1,137,836     425,707
Gross profit   $ 60,355   $ 38,614   $ 13,848   $  15,125   $ 74,203   $ 53,739
Gross profit %     5.1%     8.6%     47.5%     53.7%     6.1%     11.2%
Six Months Ended June 30,                        
(in thousands)                          
    PBM     HCIT     Consolidated
    2011   2010     2011     2010     2011   2010
Revenue     $ 2,254,778   $ 878,797   $ 54,911   $ 52,797   $ 2,309,689   $    931,594
Cost of  revenue     2,142,689     801,847     29,221     25,780     2,171,910     827,627
Gross profit   $ 112,089   $ 76,950   $ 25,690   $ 27,017   $  137,779   $ 103,967
Gross profit %     5.0%     8.8%     46.8%     51.2%     6.0%     11.2%

Revenue Q2 2011 PBM revenue was $1.2 billion, compared to $451.3 million for Q2 2010. PBM revenue for the year to date (YTD) period was $2.3 billion, compared to $878.8 million in the prior year period. The increase in revenue on a year over year basis is primarily due to new customer starts, including HealthSpring on January 1, 2011 and Optima on April 1, 2011, as well as revenues generated from the acquisition of MedfusionRx.

Q2 2011 HCIT revenue was $29.2 million, compared to $28.2 million for Q2 2010.  For the YTD period, HCIT revenue was $54.9 million, compared to $52.8 million in the prior year period. In Q2 2011, the Company experienced an increase in revenue earned from professional services and the sale of a new software license to an existing customer.

Gross Profit Consolidated gross profit for Q2 2011 was $74.2 million, an increase of $20.5 million compared to $53.7 million in Q2 2010. For the YTD period, consolidated gross profit was $137.8 million, an increase of $33.8 million compared to $104.0 million in the prior year period. The increase in consolidated gross profit was due primarily to incremental PBM revenues generated from new customers and MedfusionRx activity, as compared to the same period in 2010. Gross margin as a percentage of revenue was 6.1% for Q2 2011, compared to 11.2% in Q2 2010, due to new business wins carrying a lower gross profit percentage than the historical rates for the PBM segment.

Product Development Costs  Product development costs increased to $3.7 million in Q2 2011, compared to $3.0 million in Q2 2010.  Product development costs for the YTD period were $7.0 million, compared to $6.1 million in the prior period. Product development continues to be a key focus of the Company as it pursues the enhancement of existing products, as well as the development of new offerings, to support its market expansion.

Selling, General and Administration ("SG&A") Costs SG&A costs for Q2 2011 were $32.2 million, compared to $21.5 million in Q2 2010. SG&A costs for the YTD period were $59.7 million, compared to $42.8 million in the prior year period. The change in SG&A costs was due to additional resources to support the Company's organic growth, increased stock-based compensation and additional operating and transaction costs related to MedfusionRx and MedMetrics.

Adjusted EBITDA¹ Q2 2011 adjusted EBITDA increased 32% to $41.4 million, compared to $31.5 million in Q2 2010. Adjusted EBITDA for the YTD period was $76.6 million, compared to $59.2 million in the prior year period. The growth in adjusted EBITDA was due primarily to new contract wins, the addition of MedfusionRx and MedMetrics, HCIT-to-PBM customer conversions, and improved purchasing efficiencies on prescription drugs.

Net Income The Company reported Q2 2011 net income of $21.6 million, or $0.34 per share (fully-diluted), compared to $17.1 million, or $0.27 per share (fully-diluted), in Q2 2010. Net income for the YTD period was $39.8 million, or $0.63 per share (fully-diluted), compared to net income in the prior year period of $31.9 million, or $0.51 per share (fully-diluted).

Cash from Operations In Q2 2011, the Company used $1.4 million of cash from operations, compared to $39.5 million generated in cash from operations during Q2 2010. For the YTD period, SXC used cash from operations of $0.6 million, compared to generating $36.8 million in the prior period. The Company's cash flows were impacted by the timing of pharmacy benefit claim payments and rebate payments received. Over the course of the year these timing issues are expected to normalize and SXC expects to continue to generate strong cash flow growth on a year-over-year basis.        

At June 30, 2011 and December 31, 2010, SXC had cash and cash equivalents totalling $319.7 million and $321.3 million, respectively.  Subsequent to the quarter the Company announced an acquisition that will utilize $77 million when the transaction closes, which is expected in Q4 2011. The Company believes that its cash on hand, together with cash generated from operating activities will be sufficient to support planned operations for the foreseeable future.

2011 Full Year Financial Guidance With today's announcement, SXC is revising upward certain of its 2011 full year financial targets. The revised targets do not take into account the recently announced acquisition of PTRX and SaveDirectRx, as it has not yet closed:

  • Revenue of $4.6 to $4.7 billion, versus prior estimate of $4.3 to $4.5 billion
  • Adjusted EBITDA1 of $168 to $172 million, versus prior estimate of $165 to $171 million
  • GAAP EPS (fully-diluted) of $1.43 to $1.47, versus prior estimate of $1.40 to $1.47
  • Adjusted EPS1 (fully-diluted) of $1.58 to $1.62 versus prior estimate of $1.55 to $1.62 (excluding amortization of intangible assets).

Notice of Conference Call SXC will host a conference call on Thursday, August 4, 2011, at 8:30 a.m. ET to discuss its financial results.  Mark Thierer, Chairman, CEO and President, and Jeff Park, EVP and CFO will co-chair the call. All interested parties can join the call by dialing 1-888-231-8191 or 647-427-7450. Please dial in 15 minutes prior to the call to secure a line. The conference call will be archived for replay until Thursday, August 11, 2011 at midnight.  To access the archived conference call, please dial 1-800-642-1687 or 416-849-0833 and enter the reservation code 80900638.

A live audio webcast of the conference call will be available at and  Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast.  An archived replay of the webcast will be available for 365 days.

1Non-GAAP Financial Measures SXC reports its financial results in accordance with generally accepted accounting principles in the United States ("GAAP"). SXC's management also evaluates and makes operating decisions using various other measures. Two such measures are adjusted EPS and adjusted EBITDA, which are non-GAAP financial measures. SXC's management believes that these two measures provide useful supplemental information regarding the performance of SXC's business operations.

Adjusted EPS adds back the impact of all amortization of intangible assets, net of tax. Amortization of intangible assets arises from the acquisition of intangible assets in connection with the Company's business acquisitions. SXC excludes amortization of intangible assets from non-GAAP adjusted EPS because it believes (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of SXC's business operations and (ii) such expenses can vary significantly between periods as a result of new acquisitions and full amortization of previously acquired intangible assets. Investors should note that the use of these intangible assets contributes to revenue in the periods presented as well as future periods and should also note that such expenses will recur in future periods.

Adjusted EBITDA is a non-GAAP measure that management believes is a useful supplemental measure of operating performance prior to net interest income (expense), income taxes, depreciation, amortization and stock-based compensation expenses. Management believes it is useful to exclude depreciation, amortization and net interest income (expense) as these are essentially fixed amounts that cannot be influenced by management in the short term. In addition, management believes it is useful to exclude stock-based compensation as this is a non-cash expense.

The 2011 full year guidance of adjusted EBITDA was computed by taking the Company's estimated 2011 earnings before interest, taxes, depreciation and amortization as well as estimated stock-based compensation expense of approximately $8 to $9 million.  Adjusted EPS was computed by taking the Company's GAAP EPS (fully-diluted) guidance and adding back the expected impact of all amortization of intangible assets totaling approximately $15 million (net of an estimated 34% tax rate).

Adjusted prescription claim volume equals SXC's Mail Service prescriptions multiplied by three, plus its retail and specialty prescriptions. The Mail Service prescriptions are multiplied by three to adjust for the fact that they typically include approximately three times the amount of product days supplied compared with retail prescriptions.

Management believes that adjusted EPS, adjusted EBITDA and adjusted prescription claim volume provide useful supplemental information to management and investors regarding the performance of the Company's business operations and facilitate comparisons to its historical operating results. Management also uses this information internally for forecasting and budgeting as it believes that the measures are indicative of the Company's core operating results. Note however, that these items are performance measures only, and do not provide any measure of the Company's cash flow or liquidity. Non-GAAP financial measures should not be considered as a substitute for measures of financial performance in accordance with GAAP, and investors and potential investors are encouraged to review the reconciliations of adjusted EPS and adjusted EBITDA to their most directly comparable GAAP measure.

Adjusted EPS and adjusted EBITDA do not have standardized meanings prescribed by GAAP. The Company's method of calculating these items may differ from the methods used by other companies and, accordingly, may not be comparable to similarly titled measures used by other companies. Reconciliations of adjusted EBITDA to net income and GAAP EPS (diluted) to adjusted EPS (diluted) are shown below:

      For the Three Months Ended     For the Six Months Ended
Adjusted EBITDA Reconciliation   June 30,      June 30, 
(in thousands)   2011   2010     2011   2010
      (unaudited)     (unaudited)
Net Income (GAAP) $ 21,565   $ 17,145   $ 39,836   $ 31,937
  Amortization of Intangible Assets   3,667     1,978     7,226     3,973
  Depreciation of Property & Equipment   2,251     2,146     4,580     4,235
  Stock-Based Compensation   2,419     1,617     4,102     2,881
  Interest (Income)   (93)     (175)     (260)     (324)
  Interest Expense and Other Expense, Net 677     378     1,130       971
  Income Tax Expense   10,910     8,369     19,978       15,505
Adjusted EBITDA $  41,396   $ 31,458   $ 76,592   $ 59,178


Adjusted EPS Reconciliation For the Three Months Ended June 30,     For the Six Months Ended June 30,
(in thousands, except per share data) 2011   2010     2011   2010
    Operational Results   Per Diluted Share   Operational Results   Per Diluted Share     Operational Results   Per Diluted Share   Operational Results   Per Diluted Share
    (unaudited)     (unaudited)
Net Income (GAAP) $ 21,565   $ 0.34   $ 17,145   $ 0.27   $ 39,836   $ 0.63   $ 31,937   $ 0.51
Amortization of Intangible Assets   3,667     0.06     1,978     0.03     7,226     0.11     3,973     0.06
Tax Effect of Reconciling Item   (1,232)     (0.02)     (649)     (0.01)     (2,413)     (0.04)     (1,299)     (0.02)
Non-GAAP Net Income $ 24,000   $  0.38   $ 18,474   $  0.29   $ 44,649   $ 0.70   $  34,611   $ 0.55


About SXC Health Solutions Corp. SXC Health Solutions Corp. is a leading provider of pharmacy benefits management (PBM) services and Health Care Information Technology (HCIT) solutions to the healthcare benefits management industry. The Company's product offerings and solutions combine a wide range of PBM services and software applications, application service provider (ASP) processing services and professional services, designed for many of the largest organizations in the pharmaceutical supply chain, such as health plans, employers, federal, provincial, and, state and local governments, pharmacy benefit managers, retail pharmacy chains and other healthcare intermediaries. SXC is headquartered in Lisle, Illinois with multiple locations in the U.S. and Canada. For more information please visit

Forward-Looking Statements Certain statements included herein, including those that express management's expectations or estimates of our future performance, constitute "forward-looking statements" within the meaning of applicable securities laws.   Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management at this time, are inherently subject to significant business, economic and competitive uncertainties and contingencies.   We caution that such forward-looking statements involve known and unknown risks, uncertainties and other risks that may cause our actual financial results, performance, or achievements to be materially different from our estimated future results, performance or achievements expressed or implied by those forward-looking statements.   Numerous factors could cause actual results to differ materially from those in the forward-looking statements, including without limitation, our ability to achieve increased market acceptance for our product offerings and penetrate new markets; consolidation in the healthcare industry; the existence of undetected errors or similar problems in our software products; our ability to identify and complete acquisitions, manage our growth and integrate acquisitions; our ability to compete successfully; potential liability for the use of incorrect or incomplete data; the length of the sales cycle for our healthcare software solutions; interruption of our operations due to outside sources; our dependence on key customers; maintaining our intellectual property rights and litigation involving intellectual property rights; our ability to obtain, use or successfully integrate third-party licensed technology; compliance with existing laws, regulations and industry initiatives and future change in laws or regulations in the healthcare industry; breach of our security by third parties; our dependence on the expertise of our key personnel; our access to sufficient capital to fund our future requirements; and potential write-offs of goodwill or other intangible assets.  This list is not exhaustive of the factors that may affect any of our forward-looking statements.  Other factors that should be considered are discussed from time to time in SXC's filings with the U.S. Securities and Exchange Commission, including the risks and uncertainties discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our 2010 Annual Report on Form 10-K and subsequent Form 10-Qs, which are available at  Investors are cautioned not to put undue reliance on forward-looking statements.  All subsequent written and oral forward-looking statements attributable to SXC or persons acting on our behalf are expressly qualified in their entirety by this notice.  We disclaim any intent or obligation to update publicly these forward-looking statements, whether as a result of new information, future events or otherwise.  

Certain of the assumptions made in preparing forward-looking information and management's expectations include: maintenance of our existing customers and contracts, our ability to market our products successfully to anticipated customers, the impact of increasing competition, the growth of prescription drug utilization rates at predicted levels, the retention of our key personnel, our customers continuing to process transactions at historical levels, that our systems will not be interrupted for any significant period of time, that our products will perform free of major errors, our ability to obtain financing on acceptable terms and that there will be no significant changes in the regulation of our business.

Consolidated Balance Sheets
(in thousands, except share data) 
      June 30, 2011   December 31, 2010
Current assets            
  Cash and cash equivalents   $ 319,707   $ 321,284
  Restricted cash     14,962     13,790
  Accounts receivable, net of allowance for doubtful accounts of  $3,178 (2010 - $3,553)     227,064     122,175
  Rebates receivable     37,456     34,249
  Prepaid expenses and other assets     7,887     4,888
  Inventory     12,223     8,736
  Income tax recoverable     2,642     5,285
  Deferred income taxes     5,475     6,647
    Total current assets     627,416     517,054
  Property and equipment, net of accumulated depreciation of $38,393 (2010 - $35,861)      18,403     20,896
  Goodwill     229,764     220,597
  Other intangible assets, net of accumulated amortization of  $38,913 (2010 - $31,687)     53,556     56,282
  Deferred income taxes     501     665
  Other assets     2,445     1,296
Total assets   $ 932,085   $ 816,790
Current liabilities            
  Accounts payable   $ 38,531   $ 30,930
  Customer deposits     15,231     15,376
  Salaries and wages payable     9,861     12,833
  Accrued liabilities     18,103     21,652
  Pharmacy benefit management rebates payable      56,338     61,364
  Pharmacy benefit claims payable      144,928     84,599
  Deferred revenue     12,999     11,177
    Total current liabilities     295,991     237,931
Deferred income taxes     14,656     15,111
Other liabilities     10,119     10,492
    Total liabilities     320,766     263,534
Shareholders' equity             
  Common shares: no par value, unlimited shares authorized; 61,261,565 shares issued             
    and outstanding at June 30, 2011 (December 31, 2010 - 61,602,997 shares)     392,981     381,736
  Additional paid-in capital     31,955     24,973
  Retained earnings     186,383     146,547
    Total shareholders' equity     611,319     553,256
Total liabilities and shareholders' equity   $ 932,085   $ 816,790


Consolidated Statements of Operations
(in thousands, except  share and per share data)
        Three Months Ended June 30,     Six Months Ended June 30,  
        2011   2010     2011   2010  
        (unaudited)     (unaudited)  
  PBM   $ 1,182,856   $ 451,295   $ 2,254,778   $  878,797  
  HCIT     29,183     28,151     54,911     52,797  
Total revenue     1,212,039     479,446     2,309,689     931,594  
Cost of revenue:                          
  PBM     1,122,501     412,681     2,142,689     801,847  
  HCIT     15,335     13,026     29,221     25,780  
Total cost of revenue      1,137,836     425,707     2,171,910     827,627  
Gross profit     74,203     53,739     137,779     103,967  
  Product development costs     3,666     3,021     7,026     6,094  
  Selling, general and administrative     32,229     21,486     59,668     42,792  
  Depreciation of property and equipment     1,582     1,537     3,175     3,019  
  Amortization of intangible assets     3,667     1,978     7,226     3,973  
        41,144     28,022     77,095     55,878  
Operating income     33,059     25,717     60,684     48,089  
Interest income     (93)     (175)     (260)     (324)  
Interest expense and other expense, net     677     378     1,130     971  
Income before income taxes      32,475     25,514     59,814     47,442  
Income tax expense (benefit):                           
  Current     11,687     7,209     20,297     12,738  
  Deferred     (777)     1,160     (319)     2,767  
        10,910     8,369     19,978     15,505  
Net income   $ 21,565   $ 17,145   $ 39,836   $ 31,937  
Earnings per share:                           
  Basic   $  0.35   $ 0.28   $ 0.64   $ 0.53  
  Diluted   $ 0.34   $ 0.27   $ 0.63   $ 0.51  
Weighted average number of shares used   in computing earnings per share                          
  Basic       62,074,246     60,692,932     61,938,392       60,441,364
  Diluted       63,768,457     62,778,034     63,649,369       62,401,408


Consolidated Statements of Cash Flows
(in thousands)
      Three Months Ended June 30,     Six Months Ended June 30,  
      2011   2010     2011   2010  
      (unaudited)     (unaudited)  
Cash flows from operating activities:                      
  Net income   $ 21,565   $ 17,145   $  $ 39,836   $  $ 31,937
  Items not involving cash:                            
    Stock-based compensation     2,419     1,617     4,102     2,881
    Depreciation of property and equipment     2,251     2,146     4,580     4,235
    Amortization of intangible assets     3,667     1,978     7,226     3,973
    Deferred lease inducements and rent     (125)     (117)     (247)     (238)
    Deferred income taxes     (778)     1,160     (319)     2,767
    Tax benefit on option exercises     (5,696)     (1,506)     (9,019)     (5,588)
  Changes in operating assets and liabilities,   net of effects from acquisitions:                            
    Accounts receivable     (24,879)     4,664     (103,044)     (6,624)
    Rebates receivable     (723)     (2,801)     (401)     (17,301)
    Restricted cash     (1,160)     (16)     (1,172)     (152)
    Prepaid expenses and other assets     (2,162)     (1,412)     (2,939)     (1,571)
    Inventory     (1,304)     11     (3,487)     (1,122)
    Income tax recoverable     4,643     3,462     12,862     7,108
    Accounts payable     (209)     698     6,320     (1,685)
    Accrued liabilities     (95)     38     (7,879)     (10,696)
    Pharmacy benefit claims payable     7,609     8,909     60,329     11,246
    Pharmacy benefit management rebates payable     (7,672)     967     (7,832)     12,964
    Deferred revenue     1,293     1,719     1,815     3,107
    Customer deposits     (86)     (111)     (145)     540
    Other       66     917     (1,183)     1,020
      Net cash provided (used) by operating activities     (1,376)     39,468     (597)     36,801
Cash flows from investing activities:                      
    Acquisitions, net of cash acquired     (12,985)     -     (12,985)     -
    Purchases of property and equipment     (898)     (2,556)     (2,095)     (3,526)
    Proceeds from sale of short term investments     -     -     -     6,828
    Purchases of short term investments     -     -     -     (2,208)
    Net cash provided (used) by investing activities     (13,883)     (2,556)     (15,080)     1,094
Cash flows from financing activities:                        
    Proceeds from exercise of options     3,348     960     5,106     4,727
    Tax benefit on option exercises     5,696     1,506     9,019     5,588
    Net cash provided by financing activities     9,044     2,466     14,125     10,315
Effect of foreign exchange on cash balances       (7)     5     (25)       44
Increase (decrease) in cash and cash equivalents       (6,222)     39,383     (1,577)       48,254
Cash and cash equivalents, beginning of period        325,929     313,241     321,284       304,370
Cash and cash equivalents, end of period   $     319,707   $   352,624   $ 319,707   $ 352,624



SOURCE SXC Health Solutions Corp.